Zacks Investment Research on MSN
Here's why you should add Inogen stock to your portfolio now
Inogen, Inc. INGN is well-poised for growth in the coming quarters due to high prospects in the portable oxygen concentrator ...
Inogen, Inc. INGN has been gaining on the back of its high prospects in the portable oxygen concentrator (POC) space. Solid performance in the second quarter of 2022 and a strong product portfolio ...
Inogen, in partnership with Yuwell, has taken another step toward becoming a comprehensive respiratory solutions company with ...
Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Inogen (INGN – Research Report) yesterday and set a price target of $10.00. Discover outperforming stocks and invest smarter with ...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the introduction of ...
Inogen, Inc. INGN incurred an adjusted loss per share of 2 cents for second-quarter 2025, which was narrower than the adjusted loss per share of 7 cents in the year-ago period and the Zacks Consensus ...
Welcome to Inogen’s Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session.
Inogen (NASDAQ:INGN) shareholders have endured a 85% loss from investing in the stock five years ago
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic capital loss on anyone. Imagine if you held Inogen, Inc. (NASDAQ:INGN) for half a ...
Medical Technology company Inogen Inc (NASDAQ:INGN) reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback